<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02640313</url>
  </required_header>
  <id_info>
    <org_study_id>NL43466.068.13/ABR43466</org_study_id>
    <nct_id>NCT02640313</nct_id>
    <nct_alias>NCT01899014</nct_alias>
  </id_info>
  <brief_title>18F-choline and 18F-FDG PET-MR of Symptomatic Carotid Plaques</brief_title>
  <acronym>ESCAPPE</acronym>
  <official_title>Evaluation of Symptomatic Carotid Artery Plaques With Positron Emission Tomography-magnetic Resonance Imaging (ESCAPPE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Accumulating data in the literature suggests that radiolabeled-choline (18F-choline) is a
      sensitive molecular tracer for PET imaging that is taken up in activated cells and, as such,
      is able to identify active inflammatory sites. The investigators hypothesize that 18F-choline
      is also highly taken up in vulnerable plaques in comparison to the stable ones.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Accumulation and subsequent activation of inflammatory cells in the atherosclerotic plaques
      play an essential role in transforming a stable plaque into a vulnerable plaque at risk to
      rupture. On this basis, the study aims to evaluate the diagnostic performance of 18F-choline
      PET in identifying ongoing inflammation within atherosclerotic plaques. The investigators
      hypothesize that 18F-choline PET is efficient in detecting intraplaque inflammation and
      identify vulnerable plaques that are prone to rupture in comparison to the stable ones.

      It is likely that by correlating the inflammatory status of an atherosclerotic plaque (on
      18F-choline PET) with the presence of other vulnerable plaque features (on MR imaging) would
      be of high clinical relevance for clinical diagnosis of vulnerable plaques.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>18F-choline uptake, as marker of plaque inflammation</measure>
    <time_frame>1 year</time_frame>
    <description>To correlate the 18F-choline uptake in the atherosclerotic plaque with the degree of intraplaque inflammation, as assessed by histology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>18F-choline uptake and other markers of vulnerable plaques</measure>
    <time_frame>1 year</time_frame>
    <description>To correlate the intra-plaque 18F-choline uptake on PET with atherosclerotic plaque parameters assessed on MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>18F-choline uptake vs cardiovascular risk factors</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate a possible association between the degree of 18F-choline uptake on PET with patients' cardiovascular risk profile and medical history.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Plaque, Atherosclerotic</condition>
  <arm_group>
    <arm_group_label>18F-choline PET-MR imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: 18F-choline PET-MR imaging.
Drug: 18F-choline, dosis 4 MBq/kg body-weight (maximum 360 MBq), administered intravenously as a single dose.
Procedure: dynamic and static 18F-choline PET-MR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-choline PET-MR imaging</intervention_name>
    <description>Dynamic and static 18F-choline PET-MR imaging</description>
    <arm_group_label>18F-choline PET-MR imaging</arm_group_label>
    <other_name>PET-MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is a female or male of ay race age &gt;18 years at the time of the
             investigational product administration (no maximum age);

          -  Informed consent by signing informed consent form regarding this study;

          -  Patients known with carotid artery stenosis &gt;50%, who are scheduled for carotid
             endarterectomy.

        Exclusion Criteria:

          -  Dementia, pregnancy, nursing mothers;

          -  Patients who do have a documented allergy for CT contrast media;

          -  Patients with a renal clearance &lt;45 ml/min/1.73m2 or &lt;60 ml/min/1.73m2 in patients
             with diabetes mellitus;

          -  Serious neurological deficits at symptomatic side (hemi paralysis, complete aphasia);

          -  Severe heart failure NYHA III-IV and severe pulmonary dysfunction dependent on oxygen
             supply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Eline Kooi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Adrian Vöö, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Vöö, MD, PhD</last_name>
    <phone>+31 43 38 74746</phone>
    <email>stefan.voo@mumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Vöö, MD, PhD</last_name>
      <phone>+31 43 38 74746</phone>
      <email>stefan.voo@mumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Bucerius J, Schmaljohann J, Böhm I, Palmedo H, Guhlke S, Tiemann K, Schild HH, Biersack HJ, Manka C. Feasibility of 18F-fluoromethylcholine PET/CT for imaging of vessel wall alterations in humans--first results. Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):815-20. doi: 10.1007/s00259-007-0685-x. Epub 2008 Jan 6.</citation>
    <PMID>18183393</PMID>
  </reference>
  <reference>
    <citation>Förster S, Rominger A, Saam T, Wolpers S, Nikolaou K, Cumming P, Reiser MF, Bartenstein P, Hacker M. 18F-fluoroethylcholine uptake in arterial vessel walls and cardiovascular risk factors: correlation in a PET-CT study. Nuklearmedizin. 2010;49(4):148-53. doi: 10.3413/nukmed-0299. Epub 2010 Jun 8.</citation>
    <PMID>20532464</PMID>
  </reference>
  <reference>
    <citation>Kato K, Schober O, Ikeda M, Schäfers M, Ishigaki T, Kies P, Naganawa S, Stegger L. Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT. Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1622-8. doi: 10.1007/s00259-009-1152-7. Epub 2009 May 9.</citation>
    <PMID>19430785</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>December 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2015</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>18F-fluormethylcholine</keyword>
  <keyword>[F18] choline</keyword>
  <keyword>[F18] fluormethylcholine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

